(Q28211259)

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

23 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

23 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

23 March 2024

author name string

Sara Vasan

1

0 references

Peter Foiles

2

0 references

Hank Founds

full work available at URL

3

0 references

language of work or name

English

0 references

publication date

1 November 2003

0 references

https://api.elsevier.com/content/article/PII:S0003986103004259?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

https://api.elsevier.com/content/article/PII:S0003986103004259?httpAccept=text/plain

23 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Archives of Biochemistry and Biophysics

23 March 2024

published in

0 references

volume

419

0 references

issue

1

0 references

page(s)

89-96

0 references

cites work

Advanced glycation end-products: a review

2

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Advanced glycation end products and diabetic complications

23 March 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose

23 March 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Cellular and Molecular Biology

23 March 2024

7

44

1139

Degenhardt

1998

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification--a role in pathogenesis and antiproliferative chemotherapy.

23 March 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Monitoring the progress of non-enzymatic glycation in vitro

23 March 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients

23 March 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Immunochemical approaches to AGE-structures: characterization of anti-AGE antibodies

23 March 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Two polyclonal antisera detect different AGE epitopes in human plasma samples.

23 March 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat

23 March 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Advanced glycation end products: detection and reversal

23 March 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Membrane proteins of human erythrocytes are modified by advanced glycation end products during aging in the circulation

23 March 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Hokkaido Journal of Medical Science

23 March 2024

16

68

695

Kuwajima

1993

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction

23 March 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility

23 March 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Advanced glycation end products induce crosslinking of collagen in vitro

23 March 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats

23 March 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques.

23 March 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Early glycation products produce pentosidine cross-links on native proteins. novel mechanism of pentosidine formation and propagation of glycation

23 March 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Formation pathways for lysine-arginine cross-links derived from hexoses and pentoses by Maillard processes: unraveling the structure of a pentosidine precursor

23 March 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Identification and quantification of major maillard cross-links in human serum albumin and lens protein. Evidence for glucosepane as the dominant compound

23 March 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins.

23 March 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Cellular and Molecular Biology

23 March 2024

27

44

1159

Skovsted

1998

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct

23 March 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Protein modification by a Maillard reaction intermediate methylglyoxal. Immunochemical detection of fluorescent 5-methylimidazolone derivatives in vivo

23 March 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo

23 March 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy

23 March 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Acid-stable fluorescent advanced glycation end products: vesperlysines A, B, and C are formed as crosslinked products in the Maillard reaction between lysine or proteins with glucose

23 March 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Structure and mechanism of formation of human lens fluorophore LM-1. Relationship to vesperlysine A and the advanced Maillard reaction in aging, diabetes, and cataractogenesis.

23 March 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Amides are novel protein modifications formed by physiological sugars

23 March 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Advanced glycation end products: a Nephrologist's perspective

23 March 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Ultrastructure of nonenzymatically glycated mesangial matrix in diabetic nephropathy.

23 March 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats

23 March 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy

23 March 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat

23 March 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Immunochemical evidence for increased formation of advanced glycation end products and inhibition by aminoguanidine in diabetic rat lenses

23 March 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts

23 March 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Age-dependent accumulation of advanced glycosylation end products in human neurons.

23 March 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Relevance of the early and advanced Maillard reaction in diabetic neuropathy

23 March 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Cerebroprotective effects of aminoguanidine in a rodent model of stroke.

23 March 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Glucose: a continuous risk factor for cardiovascular disease.

23 March 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain

23 March 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases

23 March 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine

23 March 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Renoprotective effects of a novel inhibitor of advanced glycation

23 March 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy

23 March 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Amadorins: novel post-Amadori inhibitors of advanced glycation reactions.

23 March 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine

23 March 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes.

23 March 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Novel inhibitors of advanced glycation endproducts (part II).

23 March 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats

23 March 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment

23 March 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy

23 March 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Effect of chronic aminoguanidine treatment on age-related glycation, glycoxidation, and collagen cross-linking in the Fischer 344 rat.

23 March 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats

23 March 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Pimagedine: a novel therapy for diabetic nephropathy

23 March 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links

23 March 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Heart, aging, and hypertension

23 March 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes

23 March 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

The role of glycation cross-links in diabetic vascular stiffening

23 March 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Abnormalities of the extracellular degradation of collagen type I in essential hypertension

23 March 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats

23 March 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms

23 March 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Enzymatic and nonenzymatic cross-linking of collagen and elastin

23 March 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Role of extracellular matrix proteins in heart function

23 March 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats

23 March 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Effects of glucose intolerance on myocardial function and collagen-linked glycation

23 March 2024

76

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Biomechanical properties and chemical composition of the aorta in genetic hypertensive rats.

23 March 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats

23 March 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking

23 March 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Glycated collagen cross-linking alters cardiac mechanics in volume-overload hypertrophy

23 March 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

An agent cleaving glucose-derived protein crosslinks in vitro and in vivo

23 March 2024

81

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation.

23 March 2024

82

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Rapid hydrolysis and slow α,β-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links

23 March 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.

23 March 2024

85

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys

23 March 2024

86

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Breakers of advanced glycation end products restore large artery properties in experimental diabetes.

23 March 2024

87

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes

23 March 2024

88

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Improved arterial compliance by a novel advanced glycation end-product crosslink breaker

23 March 2024

89

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy.

23 March 2024

91

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Novel angiotensin II inhibitors in cardiovascular medicine

23 March 2024

92

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Accumulation of Maillard reaction products in skin collagen in diabetes and aging

23 March 2024

94

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Effects of age and diabetes mellitus on the solubility of collagen from human skin, tracheal cartilage and dura mater

23 March 2024

95

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Chelating activity of advanced glycation end-product inhibitors

23 March 2024

96

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats

23 March 2024

97

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Glucose-mediated cross-linking of collagen in rat tendon and skin.

23 March 2024

98

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Cleavage of in vitro and in vivo formed lens protein cross-links by a novel cross-link breaker

23 March 2024

99

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products

23 March 2024

100

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

CD36, a member of class B scavenger receptor family, is a receptor for advanced glycation end products.

23 March 2024

101

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice

23 March 2024

102

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

Aldosterone and myocardial fibrosis in heart failure

23 March 2024

103

1 reference

https://api.crossref.org/works/10.1016/J.ABB.2003.08.016

23 March 2024

Identifiers